Midatech Pharma Plc

Midatech Pharma Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Biodexa Pharmaceuticals Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

ABINGDON, OXFORDSHIRE / ACCESSWIRE / May 24, 2022 / Midatech Pharma PLC (AIM:MTPH)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, announces that its Notice of Annual General Meeting ("AGM") was posted to shareholders yesterday, along with the Annual Report for the year ended 31 December 2021. The documents are also available in the "Investors" section of the Company's website at www.midatechpharma.com/financial-reports-accounts.

Midatech Pharma PLC Announces Posting of Annual Report & Notice of AGM

ABINGDON, OXFORDSHIRE / ACCESSWIRE / April 26, 2022 / Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces its audited preliminary results for the year ended 31 December 2021. 2021 HIGHLIGHTS Operational · In June 2021, in an R&D update we announced: o Breakthrough data on the successful encapsulation of a biologic using Q-Sphera technology.

Midatech Pharma PLC Announces Results for the Year Ended 31 December 2021

ABINGDON, UK / ACCESSWIRE / March 9, 2022 / Midatech Pharma PLC (AIM:MTPH)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce an extension of its existing R&D collaboration with Janssen Pharmaceutica NV (Janssen) originally announced on 21 July 2020. On 17 June 2021 the Company announced that, using its Q-Sphera technology, it had successfully encapsulated a proprietary Janssen experimental large molecule medicine and importantly preserved its functional integrity.

Midatech Pharma PLC Announces R&D Collaboration with Janssen on Second Molecule

ABINGDON, UK / ACCESSWIRE / March 8, 2022 / Midatech Pharma PLC (AIM:MTPH; NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicine, is pleased to announce the appointment of Strand Hanson Limited as the Company's Nominated and Financial Adviser with immediate effect. Turner Pope Investments (TPI) Ltd will be the Company's sole broker.

Midatech Pharma PLC Announces Appointment of Nominated and Financial Adviser

Midatech announces extension of R&D collaboration with Janssen focused on Q-Sphera technology ABINGDON, UK / ACCESSWIRE / January 17, 2022 / Midatech Pharma PLC (AIM:MTPH)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce the extension of its R&D collaboration with Janssen Pharmaceutica NV (Janssen) originally announced on 21 July 2020. On 17 June 2021, the Company announced that, using its Q-Sphera technology, it had successfully encapsulated a proprietary Janssen experimental large molecule medicine and importantly preserved its functional integrity.

Midatech Pharma PLC Announces Extension of Janssen collaboration re Q-Sphera

Investigational New Drug Application for Study of MTX110 in Recurrent Glioblastoma (GBM) Becomes Effective ABINGDON, OXFORDSHIRE / ACCESSWIRE / December 13, 2021 / Midatech Pharma PLC (AIM:MTPH)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce that its Investigational New Drug (IND) application for a Phase 1 study of MTX110, a panobinostat complex to be administered by convection enhanced delivery in patients with recurrent glioblastoma multiforme (rGBM), has been cleared by the US FDA. Accordingly, Midatech has initiated preparations for a study start in the first half of 2022.

Midatech Pharma PLC Announces IND Application for MTX110 Study in GBM Effective

Midatech Pharma plc (MTP) CEO Stephen Stamp on Q2 2021 Results - Earnings Call Transcript

ABINGDON, OXFORDSHIRE / ACCESSWIRE / September 6, 2021 / Midatech Pharma PLC (AIM:MTPH)(Nasdaq:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it will release its interim results for the six months ended 30 June 2021 at 7.00 am BST on Friday 17 September 2021. The Company will be hosting a webinar at 5.30pm BST / 12.30pm EST on Monday 20 September 2021.

Midatech Pharma PLC Announces Notice of Interim Results

Midatech Pharma PLC ('Midatech' or the 'Company') Midatech Strengthens Management Team with Appointment of Dr. Dmitry Zamoryakhin as Chief Scientific Officer ABINGDON, OXFORDSHIRE / ACCESSWIRE / July 12, 2021 / Midatech Pharma PLC (AIM:MTPH; Nasdaq:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces the appointment of Dr. Dmitry Zamoryakhin as Chief Scientific Officer, a non-board role, with immediate effect. Dr. Zamoryakhin has broad experience across all phases of development of drugs and medical devices, working with regulatory authorities including the EMA, FDA, PMDA, and NMPA.

Midatech Pharma PLC Announces Appointment of Chief Scientific Officer

Midatech Pharma plc (NASDAQ: MTP) has raised £10 million from equity placing to fund its product development pipeline. Approximately 35 million new shares in the Company were issued at 28.5p each, a 12% discount on Monday's closing price.

Midatech Pharma Secures £10M In Equity To Fund Product Development

Shares of MTP stock are skyrocketing on Thursday following news of positive results from a portion of Midatech Pharma's technology. The post MTP Stock: The Big Midatech Pharma News That Has Shares Rocketing Today appeared first on InvestorPlace.

MTP Stock: The Big Midatech Pharma News That Has Shares Rocketing Today

Midatech Pharma PLC (LON: MTPH) has issued an update which has injected life into its share price. The biotech company announced what it called "breakthrough" data relating to its Q-Sphera technology, which uses 3D printing to put drugs into injectable microspheres.

Midatech Pharma surges after positive update on drug delivery technology

Midatech Pharma PLC (NASDAQ: MTP) has announced a breakthrough in vitro data utilizing Q-Sphera technology and progress across multiple other programs. The technology showed potential to formulate proteins into long-acting injectable products.

Midatech Pharma Stock Jumps After Breakthrough Data On Encapsulation Of Biologic Using Q-Sphera

The stock price of Midatech Pharma plc (NASDAQ: MTP) increased by over 35% pre-market. This is why it happened.

MTP Stock Price Increases Over 35% Pre-Market: Why It Happened

Breakthrough data on the successful encapsulation of a biologic using Q-Sphera technology Significant progress across multiple other R&D programmes ABINGDON, OXFORDSHIRE/ ACCESSWIRE / June 17, 2021 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, announces breakthrough in vitro data which demonstrate Q-Sphera's potential to formulate proteins into long-acting injectable products, as well as significant progress across multiple other programmes. In the 13 months since the announcement of a Strategic Review, the Company has shut down its Bilbao operations, thereby halving its monthly cash burn rate and pivoted from a largely singular focus on one Phase III ready asset (MTD201, Q-Sphera octreotide) to 'multiple shots on goal' with an expanded pipeline of nine earlier stage programmes.

Midatech Pharma PLC Announces Breakthrough Data Using Q-Sphera Technology

ABINGDON, UK / ACCESSWIRE / June 9, 2021 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, will be hosting an investor webinar focused on the Company's various R&D programmes at 2.00pm BST / 9.00am EST on 17 June 2021. The webinar is open to all existing and potential shareholders and those interested in attending may register via the following link, where following registration they will be provided with access details: https://us02web.zoom.us/webinar/register/WN_9dDM5-NrRWe6eMAaiGtBLA Participants may submit questions during the webinar or in advance via email to: midatech@investor-focus.co.uk For more information, please contact: Midatech Pharma PLC Stephen Stamp, CEO, CFO Tel: +44 (0)29 20480180 www.midatechpharma.com   Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker) Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking) Tel: +44 (0)20 7886 2500 Turner Pope Investments (TPI) Limited (Joint Broker) Andrew Thacker / James Pope (Corporate Broking) Tel: +44(0)20 3657 0050   IFC Advisory Limited (Financial PR and UK Investor Relations) Tim Metcalfe / Graham Herring Tel: +44 (0)20 3934 6630 Email: midatech@investor-focus.co.uk   Edison Group (US Investor Relations) Megan Paul Tel: +1 (646) 653 7034 Email: mpaul@edisongroup.com This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange.

Midatech Pharma PLC Announces Investor Webinar Scheduled for 17 June 2021

Preliminary Results for the Year Ended 31 December 2020 ABINGDON, OXFORDSHIRE / ACCESSWIRE / April 30, 2021 / Midatech Pharma PLC (AIM:MTPH.L); (NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces its audited preliminary results for the year ended 31 December 2020. Following the announcement of a Strategic Review in March 2020 and the termination of further in-house development of MTD201, the Company has broadened its R&D pipeline through technology collaborations with third party pharmaceutical companies, the initiation of new internal programmes and adding new indications to MTX110.

Midatech Pharma PLC Announces Results for the Year Ended 31 December 2020

Non-binding Heads of Terms for Co-development of MTX110; Unaudited Headline Results for the Year Ended 31 December 2020 ABINGDON, UK / ACCESSWIRE / March 25, 2021 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces the Company has agreed non-binding Heads of Terms for the co-development of MTX110 and its unaudited headline results for the year ended 31 December 2020. MTX110 - Non-binding Heads of Terms On 26 January 2021, the Company announced that it was engaged in tentative discussions with a third party around the potential co-development of MTX110.

Midatech Pharma PLC Announces MTX110 Update & Headline Results for 2020

Midatech Pharma (MTP) news for Monday includes positive results from a Phase I study of a DIPG treatment boosting MTP stock higher. The post Midatech Pharma News: Why MTP Stock Is Surging 10% Today appeared first on InvestorPlace.

Midatech Pharma News: Why MTP Stock Is Surging 10% Today

Midatech Pharma plc (MTP) CEO Craig Cook on Q2 2020 Results - Earnings Call Transcript

Midatech Pharma (MTP) news for Friday includes talk from the company about reselling roughly 12.7 million shares pushing MTP stock higher.
The post Midatech Pharma News: Why MTP Stock Is Soaring 56% Today appeared first on InvestorPlace.

Midatech Pharma News: Why MTP Stock Is Soaring 56% Today

Midatech Pharma (MTP) news for Tuesday concerning a collaboration deal involving the Q-Sphera platform has MTP stock taking off.
The post Midatech Pharma News: Why MTP Stock Is Skyrocketing 154% Today appeared first on InvestorPlace.

Midatech Pharma News: Why MTP Stock Is Skyrocketing 154% Today

A stronger diabetes vaccine may be what the doctor will order soon as Midatech Pharma's clinical trial were "positive." MTP stock is up.

Midatech Pharma News: MTP Stock Rockets on Diabetes Vaccine Results

Midatech Pharma PLC-ADR (NASDAQ: MTP) shares were trading higher Friday after the company announced positive results from a first-in-human study of its MTX102 immuno-tolerizing vaccine product candidate in diabetes.

Midatech Pharma Rallies On Positive MTX102 Results

The U.S.-listed shares of Midatech Pharma PLC rocketed 113% on very heavy volume in premarket trading Friday.

News for Midatech Pharma Plc Stock (MTP)